Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules (ALTITUDE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04171492 |
|
Recruitment Status :
Recruiting
First Posted : November 21, 2019
Last Update Posted : November 25, 2022
|
Sponsor:
Biodesix, Inc.
Information provided by (Responsible Party):
Biodesix, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer.
| Condition or disease |
|---|
| Nodule Solitary Pulmonary Non-small Cell Carcinoma |
A multicenter, randomized controlled study with a blinded control arm. Open label arm is observational for lung nodule management. The clinical trial will evaluate the clinical utility of the Nodify XL2 integrated classifier when used in the clinical management of newly identified solid lung nodules assessed as < 50% risk of cancer by Mayo risk prediction algorithm.
| Study Type : | Observational |
| Estimated Enrollment : | 2000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Classifier in Incidentally Discovered Low to Moderate Risk Lung Nodules |
| Actual Study Start Date : | December 18, 2020 |
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | December 2026 |
| Group/Cohort |
|---|
|
Open Label
Nodify XL2 results will be reported to the investigator and available to the subject.
|
|
Blinded
Nodify XL2 results will not be available to the investigative site or subject.
|
Primary Outcome Measures :
- Lung Nodule Diagnosis [ Time Frame: Up to 24 months ]Malignant diagnosis through histology/pathology or benign diagnosis through histology/pathology, radiologic stability or radiologic confirmation of nodule resolution
Biospecimen Retention: Samples Without DNA
Nodify XL2 plasma sample
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Sampling Method: | Probability Sample |
Study Population
Subjects with newly identified, solid lung nodule determined to be low-moderate risk of cancer.
Criteria
Inclusion Criteria:
- Subject has provided informed consent to participate in the study and agrees to comply with all protocol requirements
- Subject is > 40 years of age at the time of the discovery of the lung nodule of concern
-
Subject's lung nodule of concern meets the following:
- Was incidentally identified or detected during lung cancer screening
- Is a solid nodule
- Has maximal dimension of > 8mm and < 30mm
- The first CT scan identifying the lung nodule of concern was performed within 60 days of subject enrollment
- The pre-test risk of cancer as determined by the Mayo risk prediction algorithm is 65% or less
Exclusion Criteria:
- Nodule work-up at the time of subject enrollment indicating any prior attempted or completed diagnostic biopsy procedure or blood-based testing for the lung nodule of concern
- Nodule of concern is part-solid or Ground Glass Opacity (GGO)
- Prior diagnosis of lung cancer
- Any active cancer within 5-years of nodule detection, with the exception of non-melanoma skin cancer
- Administration of blood products (i.e. packed red blood cells, fresh frozen plasma, or platelets) within 30 days of subject enrollment
- Concurrent participation in any unrelated clinical trial that may impact or alter the management of the subject's nodule of concern
- Any illness or factor that will inhibit compliance with study participation
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04171492
Contacts
| Contact: Russell F Hudnall | 360-801-1658 | russell.hudnall@biodesix.com | |
| Contact: Niki Givens | niki.givens@biodesix.com |
Locations
Show 24 study locations
Sponsors and Collaborators
Biodesix, Inc.
Investigators
| Principal Investigator: | Leona Hamrick, DHSc, PA-C | Biodesix, Inc. | |
| Principal Investigator: | Gerard Silvestri, MD | Medical University of South Carolina |
| Responsible Party: | Biodesix, Inc. |
| ClinicalTrials.gov Identifier: | NCT04171492 |
| Other Study ID Numbers: |
BDX-CD-003 |
| First Posted: | November 21, 2019 Key Record Dates |
| Last Update Posted: | November 25, 2022 |
| Last Verified: | November 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |